Velcade
NICE recommends Janssen’s Darzalex myeloma combo
March 12, 2019Manufacturing and Production Janssen, NICE, Velcade, darzalex, myeloma
Britain’s cost effectiveness body NICE have recommended Janssen Pharmaceutical’s Darzalex in combination with Velcade and dexamethasone (DVd), for use within …
NICE recommends Velcade for MCL, and three diabetes drugs
December 23, 2015Sales and Marketing Forxiga, NICE, Velcade, invokana, jardiance, mantel cell lymphoma, mcl
NICE has published final guidance recommending Velcade (bortezomib) as a treatment for previously untreated mantle cell lymphoma (MCL). In the …
Amgen’s Kyprolis doubles Velcade benefit in head-to-head study
December 5, 2015Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma
Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …
Challenges in oncology R&D
November 18, 2015Manufacturing and Production, Research and Development Dixie-Lee Esseltine, Takeda, Takeda oncology, Velcade, multiple myeloma, oncology
Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …
Takeda in Velcade patent blow
August 25, 2015Manufacturing and Production Actavis, Sandoz, Takeda, Velcade, bortezomib, ixazomib
Takeda has lost a court case contesting the patent for its blockbuster multiple myeloma drug Velcade, in a decision that …
J&J blood cancer drug gets UK launch
March 25, 2015Sales and Marketing Cancer, J&J, JJ, Janssen, NICE, Velcade, bortezomib, mcl, nhl
Johnson and Johnson’s pharma unit Janssen is launching Velcade in the UK for the first-line treatment of Mantle Cell Lymphoma …
FDA in Novartis cancer drug U-turn
February 24, 2015Research and Development, Sales and Marketing Cancer, FDA, Farydak, Novartis, Revlimid, Velcade, myeloma
The FDA has overturned an earlier advisory committee recommendation and decided to approve Novartis’ blood cancer drug Farydak. In November …
Olysio and Xarelto boost J&J’s Q4
January 21, 2015Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four
Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …
Patient access schemes ‘lack transparency’
December 12, 2014Research and Development, Sales and Marketing Janssen, NHS, NICE, Velcade, patient access, pharma, scheme
Deals negotiated between the pharma industry and governments to allow patients access to innovative new cancer treatments risk failing because …
Takeda eyes new drug licences following positive blood cancer studies
December 11, 2014Research and Development, Sales and Marketing Adcetris, Takeda, Velcade, ash, bortezomib, brentuximab vedotin, hematology
Takeda is bringing its biotech arm in-house to create a global oncology business unit, which it says will drive forward …
NICE approves Velcade
March 21, 2014Sales and Marketing Janssen, NHS, NICE, Velcade, myeloma
NICE has recommended Janssen’s proteasome inhibitor Velcade as an induction treatment for some patients with newly-diagnosed multiple myeloma. The draft …
Janssen/Pharmacyclics gain FDA nod for Imbruvica
November 14, 2013Sales and Marketing FDA, Janssen, Pharmacyclics, Revlimid, Velcade
The FDA has approved Janssen and Pharmacyclics’ Imbruvica to treat patients with mantle cell lymphoma (MCL), a rare and aggressive …
NICE needs more Velcade data
November 12, 2013Sales and Marketing NHS, NICE, Velcade, eric low
NICE has slowed the progress of Janssen Cilag’s Velcade towards becoming an NHS treatment for multiple myeloma by asking the …
Johnson & Johnson posts strong Q3 results
October 16, 2013Sales and Marketing J&J, JJ, Q3, Velcade, results
Johnson & Johnson has posted a strong set of financials for the third quarter as new products from its pharma …
Celgene’s multiple myeloma pill launched in UK
August 15, 2013Sales and Marketing Celgene, Velcade, low, myeloma
Celgene’s new oral blood cancer drug pomalidomide has been launched in the UK and Ireland as a third line treatment …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
